New research builds on Nobel-winning immune checkpoint blockade work
Immunotherapy’s promise in the fight against cancer drew international attention after two scientists won a Nobel Prize this year for unleashing the ability of the immune system to eliminate tumor cells.
But their approach, which keeps cancer cells from shutting off the immune system’s powerful T-cells before they can fight tumors, is just one way to use the body’s natural defenses against deadly disease. A team of Vanderbilt University bioengineers today announced a major breakthrough in another: penetrating tumor-infiltrating immune cells and flipping on a switch that tells them to start fighting. The team designed a nanoscale particle to do that and found early success using it on human melanoma tissue.
“Tumors are pretty conniving and have evolved many ways to evade detection from our immune system,” said John T. Wilson, assistant professor of chemical and biomolecular engineering and biomedical engineering. “Our goal is to rearm the immune system with the tools it needs to destroy cancer cells.
“Checkpoint blockade has been a major breakthrough, but despite the huge impact it continues to have, we also know that there are a lot of patients who don’t respond to these therapies. We’ve developed a nanoparticle to find tumors and deliver a specific type of molecule that’s produced naturally by our bodies to fight off cancer.”
That molecule is called cGAMP, and it’s the primary way to switch on what’s known as the stimulator of interferon genes (STING) pathway: a natural mechanism the body uses to mount an immune response that can fight viruses or bacteria or clear out malignant cells. Wilson said his team’s nanoparticle delivers cGAMP in a way that jump-starts the immune response inside the tumor, resulting in the generation of T-cells that can destroy the tumor from the inside and also improve responses to checkpoint blockade.
While the Vanderbilt team’s research focused on melanoma, their work also indicates that this could impact treatment of many cancers, Wilson said, including breast, kidney, head and neck, neuroblastoma, colorectal and lung cancer.
His findings appear today in a paper titled “Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy” in the journal Nature Nanotechnology.
Daniel Shae, a Ph.D. student on Wilson’s team and first author of the manuscript, said the process began with developing the right nanoparticle, built using “smart” polymers that respond to changes in pH that he engineered to enhance the potency of cGAMP. After 20 or so iterations, the team found one that could deliver cGAMP and activate STING efficiently in mouse immune cells, then mouse tumors and eventually human tissue samples.
“That’s really exciting because it demonstrates that, one day, this technology may have success in patients,” Shae said.
Learn more: Nanoparticle targets tumor-infiltrating immune cells, flips switch telling them to fight
The Latest on: Cancer Immunotherapy
[google_news title=”” keyword=”cancer Immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer Immunotherapy
- Research finds the protein VISTA directly blocks T cells from functioning in immunotherapyon May 17, 2024 at 11:00 am
A Cleveland Clinic-led team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment ...
- Gut bacteria enhance cancer immunotherapy in mouse studyon May 17, 2024 at 11:00 am
Roughly one in five cancer patients benefit from immunotherapy—a treatment that harnesses the immune system to fight cancer. Such an approach to beating cancer has seen significant success in lung ...
- US FDA approves Amgen drug for small cell lung canceron May 17, 2024 at 10:56 am
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for treating adults with advanced small cell lung cancer that has ...
- Most cancer treatments are useless for patients with advanced tumors near end of lifeon May 17, 2024 at 8:27 am
Cutting-edge cancer treatments are essentially useless for patients barely clinging to life, a new study shows.
- Amgen's 'watershed' lung cancer drug nabs FDA nod in deadly, tough-to-treat form of the diseaseon May 17, 2024 at 5:12 am
Seven months after Amgen’s chief medical officer referred to trial results for the company's investigational lung cancer immunotherapy as a “watershed moment,” the FDA has signed off on Imdelltra ...
- Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung canceron May 16, 2024 at 7:33 pm
Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy -- given before and after surgery -- significantly improved event-free survival (EFS) in patients with ...
- Here’s what to know about innovative treatment Dr. Richard Scolyer used on his own deadly cancer: ‘A Hail Mary’on May 16, 2024 at 12:25 pm
The doctor, who himself is a pathologist who has helped pioneer melanoma treatments, tried a first-of-its-kind combination of immunotherapy drugs prior to surgery in a revolutionary new approach.
- Immunotherapy may boost survival after lung cancer surgeryon May 16, 2024 at 9:19 am
Immunotherapy can boost the survival of early-stage lung cancer patients eligible for surgery when it's combined with chemotherapy, a new clinical trial reports.
- This time, it's personal: Enhancing patient response to cancer immunotherapyon May 15, 2024 at 12:12 pm
Immunotherapy has revolutionized the way we treat cancer in recent years. Instead of targeting the tumor itself, immunotherapies work by directing patients' immune systems to attack their tumors more ...
- PDS Biotechnology Corp. (NASDAQ:PDSB) Uses Cancer Immunotherapy to Infiltrate and Disable Tumors from Withinon May 14, 2024 at 11:32 am
PDS Biotechnology is a clinical development company working on cancer immunotherapy treatments, with a current focus on HPV-related cancers.
via Bing News